pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,087 catalysts · 4,728 grant · 4,071 device 510k · 3,114 approval · 3,057 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 28 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: approval×type: recall×from 2025-01-08×clear all
type
  • grant4,728
  • device 510k4,071
  • approval3,114
  • 8k filing3,057
  • device pma2,000
  • device recall2,000
device adverse event
1,000
  • recall973
  • earnings583
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Jan 6, 2025

    14
    ›Jan 8, 2025approval580d agoLAMOTRIGINE — FDA approvalZydus Therapeutics Inc

    Sponsor: ZYDUS PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 8, 2025recall580d agoAvKARE recall (Cls III)AvKare LLC

    Carboxymethylcellulose Sodium Ophthalmic Solution 0.5% Moisturizing Lubricant Eye Drops, 0.5 FL OZ (15 mL) bottles, Distributed by: AvKARE, Pulaski, TN, 38478, NDC 50268-068-15. — Reason: LABELING: LABEL MIX-UP — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoVIONA PHARMACEUTICALS INC recall (Cls II)IONIS PHARMACEUTICALS INC

    Dapsone Gel 7.5%, 90 g, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Viona Pharmaceuticals Inc., Cranford, NJ 07016, NDC 72578-094-03. packaged in an Airless pump pack — Reason: Crystallization — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoAvKARE recall (Cls II)AvKare LLC

    Nitrofurantoin Capsules, USP, 100 mg, 50 Capsules (5 x 10) Unit Dose per carton, Rx Only, Manufactured for: AvKARE, Inc., Pulaski, TN 38478. NDC#: 50268-625-15. — Reason: Failed Dissolution Specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoLupin Pharmaceuticals Inc. recall (Cls II)LB PHARMACEUTICALS INC

    Levothyroxine Sodium Tablets, Lupin, 75 mcg (0.075mg), 1000 Tablets, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited, Pithampur (M.P)- 454 775 INDIA, NDC# 68180-967-03 — Reason: Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study. — Status: Terminated

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoHikma Injectables USA Inc recall (Cls II)NRX Pharmaceuticals, Inc.

    ketamine inj 50 mg per 1 mL, Rx Only, 1 mL fill in a 3mL pre-filled syringe, For IV or IM Use, Hikma Injectables USA Inc., 36 Stults Road, Dayton, NJ 08810, This is a Compounded Drug. Hospital/Office Use Only. NDC 63037-137-25 — Reason: Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment. — Status: Terminated

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoGNMart LLC recall (Cls I)OCULAR THERAPEUTIX, INC

    FORCE FOREVER 400mg Tablets, Huesos y articulaciones sin dolor, SUPLEMENTO ALIMENTICIO, 60-count bottles — Reason: Marketed without an approved NDA/ANDA. FDA analysis found the product to be tainted with Diclofenac and Dexamethasone. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoHikma Injectables USA Inc recall (Cls II)Revalesio Corp

    phenylephrine in 0.9% Sodium Chloride Inj, 1mg per 10 mL (100 mcg/mL), Rx only, Hikma Injectables USA Inc., 36 Stults Road, Dayton, NJ 08810, NDC 63037-173-25 — Reason: Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment. — Status: Terminated

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoSOMERSET THERAPEUTICS LLC recall (Cls III)Somerset Therapeutics LLC

    Atropine Sulfate Ophthalmic Solution, USP 1%, 5 mL bottles, Rx only, Manufactured for: Somerset Therapeutics, LLC. Somerset, NJ 08873, NDC 70069-716-01 — Reason: Failed Impurities/Degradation Specifications — Status: Terminated

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoVIONA PHARMACEUTICALS INC recall (Cls II)IONIS PHARMACEUTICALS INC

    Dapsone Gel 7.5%, 60 g, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahemedabad, India, Distributed by: Viona Pharmaceuticals Inc., Cranford, NJ 07016, NDC 72578-094-02. packaged in an Airless pump pack — Reason: Crystallization — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 8, 2025recall580d agoAvKARE recall (Cls III)AvKare LLC

    Polyvinyl Alcohol Ophthalmic Solution 1.4%, Moisturizing Lubricant Eye Drops, 0.5 FL OZ (15 mL) bottles, Distributed by AvKARE, Pulaski, TN 38478, www.avkare.com, NDC 50268-678-15 — Reason: LABELING: LABEL MIX-UP — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 10, 2025approval578d agoFLONASE SENSIMIST ALLERGY RELIEF (FLUTICASONE FUROATE) — FDA approvalGlaxoSmithKline LLC

    Sponsor: HALEON US HOLDINGS. Form: SPRAY, METERED. Route: NASAL

    full page →fda approvals ↗
    ›Jan 10, 2025approval578d agoFLONASE ALLERGY RELIEF (FLUTICASONE PROPIONATE) — FDA approvalParatek Pharmaceuticals Inc

    Sponsor: HALEON US HOLDINGS. Form: SPRAY, METERED. Route: NASAL

    full page →fda approvals ↗
    ›Jan 10, 2025approval578d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗

    Week of Jan 13, 2025

    26
    ›Jan 13, 2025approval575d agoLURASIDONE HYDROCHLORIDE — FDA approvalLURASIDONE HYDROCHLORIDE

    Sponsor: TORRENT. Form: TABLET. Route: ORAL

    full page →LURASIDONE HYDROCHLORIDE →fda approvals ↗
    ›Jan 15, 2025approval

    Week of Jan 20, 2025

    10
    ›Jan 21, 2025approval567d agoPOTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approvalmogamulizumab

    Sponsor: KYOWA KIRIN. Form: INJECTABLE. Route: INJECTION

    full page →mogamulizumab →fda approvals ↗
    ›Jan 21, 2025approval
    ← prev
    page 1 of 82
    next →
    573d ago
    OMVOH (MIRIKIZUMAB-MRKZ) — FDA approvalmirikizumab

    Sponsor: ELI LILLY AND CO. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →mirikizumab →fda approvals ↗
    ›Jan 15, 2025approval573d agoOMVOH (MIRIKIZUMAB-MRKZ) — FDA approvalmirikizumab

    Sponsor: ELI LILLY AND CO. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →mirikizumab →fda approvals ↗
    ›Jan 15, 2025recall573d agoEndo USA, Inc. recall (Cls I)Par Pharmaceutical Inc

    Clonazepam Orally Disintegrating Tablets, USP, 0.125 mg, C-IV, Rx Only, 60 tablets per carton (10 blister cards containing 6 tablets each), Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977, NDC#: 49884-306-02 (carton), NDC #: 49884-306-52 (blisters). — Reason: Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoFDC Limited recall (Cls II)FDC Ltd

    Ciprofloxacin Ophthalmic Solution USP, 0.3% as base, Sterile, package in 5 mL bottles, Rx Only, Distributed by: Leading Pharma LLC, Fairfield, NJ. Manufactured by: FDC Limited, Maharashtra, India, NDC 69315-308-05 — Reason: Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoGranules Pharmaceuticals Inc. recall (Cls II)LB PHARMACEUTICALS INC

    Colchicine Capsules 0.6 mg, 30-count bottles, Rx only, Manufactured by: Granules Pharmaceuticals Inc. Chantilly, VA 20151 NDC 70010-001-03 — Reason: Failed Dissolution Specifications: Out of specification observed during the accelerated stability conditions for the 30 count bottles. — Status: Terminated

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoEugia US LLC recall (Cls II)Eugia US LLC

    Progesterone Injection USP, 500mg per 10 mL (50mg/mL), 10 mL Multiple Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC. E. Windsor NJ 08520 NDC # 55150-306-10 — Reason: Presence of Particulate Matter: A market complaint was received of a glass piece in the vial. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoJubilant Draximage Inc., dba Jubilant Radiopharma recall (Cls II)Jubilant DraxImage Inc

    Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection, 10 mL Multi-Dose Reaction Vial, 5 vial Box, Rx Only, Manufactured for: Jubilant Draximage Inc., dba Jubilant Radiopharma, Kirkland , Quebec, H9H, 4J$, Canada, NDC# 65174-179-05. — Reason: Failed Stability Specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoRising Pharma Holding, Inc. recall (Cls II)CHINA PHARMA HOLDINGS, INC.

    Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ — Reason: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoBuy-Herbal recall (Cls I)OCULAR THERAPEUTIX, INC

    Nhan Sam Tuyet Lien Truy Phong Hoan, Capsules, 30-Count Bottles, Manufactured by Yee Hong Pharmaceuticals, SDN, Penang, Malasia. — Reason: Marketed without an Approved NDA/ANDA: FDA analysis found the products to be tainted with undeclared Furosemide, Dexamethasone and Chlorpheniramine — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoEndo USA, Inc. recall (Cls I)Par Pharmaceutical Inc

    Clonazepam Orally Disintegrating Tablets, USP, 1 mg, C-IV, Rx Only, 60 tablets per carton (10 blister cards containing 6 tablets each), Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977, NDC#: 49884-309-02 (carton), NDC #: 49884-309-52 (blisters). — Reason: Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoWest-Ward Columbus Inc recall (Cls III)Hikma Pharmaceuticals USA Inc

    Methadone Hydrochloride Tablets, USP, 5mg, 10x10 Unit-Dose Tablets, Rx Only, Distributed by: Hikma Pharmaceuticals USA Inc., Berkeley Heights, NJ 07922, NDC 0054-0709-20 — Reason: Failed Tablet/Capsule Specifications: Illegible product identification for the unit dose configuration only. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoEugia US LLC recall (Cls II)Eugia US LLC

    medroxyPROGESTERone Acetate Injectable Suspension, USP, 150mg per mL, Rx only, 1 mL Single-Dose Vial, Mfd in India for: Eugia US LLC, NJ 08520 NDC 55150-329-01 Shipper label: medroxyPROGESTERone Acetate Injectable Suspension, USP, 150 mg per mL, Distributed by: Eugia US LLC, NJ, Manufactured by: Eugia Pharma Specialties Limited, India — Reason: CGMP Deviations — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoAmerisource Health Services LLC recall (Cls II)Taro Pharmaceutical Laboratories Inc (Inactive)

    Clobazam Tablets, 10 mg, packaged in 30 tablets per carton (3x10 blister cards each), Rx Only, Amneal Pharmaceuticals LLC, Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 60687-423-21 — Reason: Presence of Foreign Tablets/Capsules — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoRising Pharma Holding, Inc. recall (Cls II)CHINA PHARMA HOLDINGS, INC.

    Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ — Reason: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoEndo USA, Inc. recall (Cls I)Par Pharmaceutical Inc

    Clonazepam Orally Disintegrating Tablet, USP, 2 mg, C-IV, Rx Only, 60 Tablets per carton, 10 blister cards containing 6 tablets each, Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977, NDC#: 49884-310-02 (carton), NDC#: 49884-310-52 (blisters). — Reason: Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoGranules Pharmaceuticals Inc. recall (Cls II)LB PHARMACEUTICALS INC

    Metformin Hydrochloride Extended-Release Tablets, USP, 500 mg, 1000-count bottles, Rx Only, Manufactured by: Granules India Limited, Hyderabad- 500 081, India, Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Grand Cayman Islands, NDC 82009-117-10 — Reason: Presence of Foreign Tablets/Capsules: A Paracetamol 500 mg tablet was found in a 1000-count bottle of Metformin HCL ER Tablets USP, 500 mg. — Status: Terminated

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoEndo USA, Inc. recall (Cls I)Par Pharmaceutical Inc

    Clonazepam Orally Disintegrating Tablets, USP, 0.25 mg, C-IV, Rx Only, 60 tablets per carton (10 blister cards containing 6 tablets each), Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977, NDC#: 49884-307-02 (carton), NDC #: 49884-307-52 (blisters). — Reason: Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 15, 2025recall573d agoRising Pharma Holding, Inc. recall (Cls II)CHINA PHARMA HOLDINGS, INC.

    Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ NDC 57237-017-60 — Reason: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 16, 2025approval572d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jan 16, 2025approval572d agoARTESUNATE — FDA approvalARTESUNATE

    Sponsor: AMIVAS. Form: POWDER. Route: INTRAVENOUS

    full page →ARTESUNATE →fda approvals ↗
    ›Jan 16, 2025approval572d agoCALQUENCE (ACALABRUTINIB MALEATE) — FDA approvalCALQUENCE

    Sponsor: ASTRAZENECA. Form: TABLET. Route: ORAL

    full page →CALQUENCE →fda approvals ↗
    ›Jan 16, 2025approval572d agoCALQUENCE (ACALABRUTINIB) — FDA approvalCALQUENCE

    Sponsor: ASTRAZENECA. Form: CAPSULE. Route: ORAL

    full page →CALQUENCE →fda approvals ↗
    ›Jan 17, 2025approval571d agoSPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: SPRAY. Route: NASAL

    full page →fda approvals ↗
    ›Jan 17, 2025approval571d agoELELYSO (TALIGLUCERASE ALFA) — FDA approvaltaliglucerase alfa

    Sponsor: PFIZER. Form: POWDER. Route: INTRAVENOUS

    full page →taliglucerase alfa →fda approvals ↗
    ›Jan 17, 2025approval571d agoPEPCID COMPLETE (CALCIUM CARBONATE) — FDA approvalKenvue Inc.

    Sponsor: KENVUE BRANDS. Form: TABLET, CHEWABLE. Route: ORAL

    full page →fda approvals ↗
    567d ago
    EPYSQLI (ECULIZUMAB-AAGH) — FDA approvalEPYSQLI

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTION. Route: SOLUTION

    full page →EPYSQLI →fda approvals ↗
    ›Jan 21, 2025approval567d agoADDYI (FLIBANSERIN) — FDA approvalSprout2 Inc

    Sponsor: SPROUT PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 22, 2025approval566d agoHALOPERIDOL — FDA approvalHALOPERIDOL

    Sponsor: AIPING PHARM INC. Form: TABLET. Route: ORAL

    full page →HALOPERIDOL →fda approvals ↗
    ›Jan 22, 2025approval566d agoFINGOLIMOD HYDROCHLORIDE — FDA approvalFINGOLIMOD HYDROCHLORIDE

    Sponsor: AUROBINDO PHARMA LTD. Form: CAPSULE. Route: ORAL

    full page →FINGOLIMOD HYDROCHLORIDE →fda approvals ↗
    ›Jan 22, 2025approval566d agoZYPREXA ZYDIS (OLANZAPINE) — FDA approvalDR REDDYS LABORATORIES LTD

    Sponsor: CHEPLAPHARM. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →fda approvals ↗
    ›Jan 22, 2025approval566d agoZYPREXA RELPREVV (OLANZAPINE PAMOATE) — FDA approvalCHEPLAPHARM Arzneimittel GmbH

    Sponsor: CHEPLAPHARM. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 22, 2025approval566d agoZYPREXA (OLANZAPINE) — FDA approvalTEVA PHARMACEUTICAL INDUSTRIES LTD

    Sponsor: CHEPLAPHARM. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 22, 2025approval566d agoZYPREXA (OLANZAPINE) — FDA approvalTEVA PHARMACEUTICAL INDUSTRIES LTD

    Sponsor: CHEPLAPHARM. Form: POWDER. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 22, 2025approval566d agoLYBALVI (OLANZAPINE) — FDA approval(olanzapine + samidorphan l-malate)

    Sponsor: ALKERMES INC. Form: TABLET. Route: ORAL

    full page →(olanzapine + samidorphan l-malate) →fda approvals ↗
    $LBRX45.85-4.48%
    $NRXP
    $IONS56.94+0.67%
    $IONS56.94+0.67%
    $OCUL9.2400+0.54%
    $GILD133.06-0.11%
    $LLY1231.94+3.90%
    $LLY1231.94+3.90%
    $CPHI0.7101-0.82%
    $LBRX45.85-4.48%
    $OCUL9.2400+0.54%
    $CPHI0.7101-0.82%
    $CPHI0.7101-0.82%
    $LBRX45.85-4.48%
    $AZN161.91+0.30%
    $PFE27.05+1.08%
    $KVUE19.03-1.04%
    $AZN161.91+0.30%
    $TEVA36.14+2.21%
    $RDY12.15-0.57%
    $TEVA36.14+2.21%
    $ALKS49.40+0.47%